34th Annual Miami Breast Cancer Conference®

Start

Thu, 9 Mar 2017, 12:50

End

Sun, 12 Mar 2017, 01:00

WebSite

http://www.gotoper.com/conferences/mbcc/meetings/34th-Annual-Miami-Breast-Cancer-Conference

Hashtag:

#PER_MBC

Venue:

Find Physicians' Education Resource on Social Media

Exhibit

Symposia

Workshops

Organiser

Sponsor

Overview

The optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medical interventions. The multidisciplinary Miami Breast Cancer Conference® has been bringing together surgical, medical, and radiation oncologists, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging crossteam cooperation in the clinic. At Miami Breast Cancer Conference®, pioneers of innovative approaches in each of these subspecialties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.

2017 Can’t-Miss Topics

Updates in immunology and immunotherapy
The latest updates and controversies in systemic therapy, including:
- State-of-the-art therapy for early-stage disease
- Anthracycline-sparing approaches for HER2+ breast cancer
- Optimized therapeutic strategies across the disease continuum
- What constitutes a true HER2+ test result?
- Targeted therapies (eg, CDK4/6 inhibition, PARP inhibition, HER2-negative, and androgen receptor targeted agents)
- Novel and emerging therapies and biological paradigms
- Overcoming therapeutic resistance
- Endocrine blockade for ductal carcinoma in situ
Assessing and reducing breast cancer risk, including:
- What are the clinical utilities of the 70-gene versus the 21-gene and other breast cancer recurrence assays?
- Should biologic factors be incorporated into breast cancer staging?
- How should we choose multiparameter genomic assays in early-stage breast cancer?
- Germline mutation testing update
- Delivery of cancer genetic services
Critical evaluation of contemporary surgical approaches, including:
- Is the TRAM flap dead?
- Prepectoral technique in breast reconstruction
- Optimized approaches toward breast-conserving therapy, axillary dissection, and surgical margins
- Oncoplastic surgery
- Opioid-sparing pain management strategies
Standards of care and controversies in radiation therapy (RT), including:
- Postmastectomy RT in patients with 1-3 nodes
- Extended-field RT
New frontiers in cancer imaging, diagnostics, and treatment, including:
- Radiomics and radiogenomics
- Where are we with circulating tumor cells and cell-free DNA?
- Preoperative MRI in breast-conserving therapy
- Is tomosynthesis mammography ready for prime time?
Cardio-oncology
- New technologies for diagnosis and management of breast-cancer‒associated cardiomyopathy
- Cellular-based therapy for anthracycline-induced cardiomyopathy
- Novel treatment options for chemotherapy-induced cardiomyopathy
Sexuality and fertility
Practice management, including:
- The doctor‒patient relationship in the era of precision medicine
- Is breast surgical oncology a dying specialty?
- What does the future hold for academic medical centers versus academic medical systems?
- How will the Medicare Access and CHIP Reauthorization Act (MACRA) affect breast cancer practice?
- Value comparison of local therapy treatment approaches in early-stage breast cancer

And much more!!

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.

Pre-Registration will close as of March 7th at 12:00pm ET. On-site registration will begin March 9th.

	Mini Symposium* & Main Conference March 9 - 12, 2017		Main Conference Only March 10 - 12, 2017
	Advance Ends 3/7	On-Site	Advance Ends 3/7	On-Site
Physicians	$1,189	$1,299	$859	$899
Fellows**	$999	$1,099	$659	$699
Nurses, PAs, Other Health Care Professionals	$999	$1,099	$659	$699
Industry***	$1,349	$1,499	$999	$1,099
Guest (access to receptions only)*	$229	$249	$199	$249

*Discount does not apply to the Mini-Symposium or Guest Registration.
**FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount.
***INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

A cancellation fee of 25% will be assessed on refunds requested through and including January 28, 2017, and a 50% fee on refunds requested on January 29, 2017, through February 25, 2017. No refunds will be made after February 25, 2017. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.